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a b s t r a c t
Secretion of 27-hydroxycholesterol (27OHC) from macrophages is considered as an alternative to HDL-
mediated reverse transport of excess cholesterol. We investigated 27OHC-concentrations in plasma
of humans and mice with monogenic disorders of HDL metabolism. As compared to family con-
trols mutations in the genes for apolipoprotein A-I, ATP binding cassette transporter (ABC) A1 and
lecithin:cholesterol acylstransferase (LCAT) were associated with reduced concentrations of both HDL-
cholesterol and HDL-27OHC whereas mutations in the genes for cholesterylester transfer protein (CETP),
scavenger receptor type BI and hepatic lipasewere associatedwith elevatedHDL concentrations of either
sterol. Compared to family controls and relative to the concentrations of total 27OHC and cholesterol,
lower 27OHC-ester but normal cholesterylester levels were found in HDL of heterozygous LCAT muta-
tion carriers and nonHDL of heterozygous CETP mutation carriers. In family controls, LCAT activity and
CETP mass were more strongly correlated with 27OHC-ester than cholesterylester concentrations in HDL
and nonHDL, respectively. These ﬁndings suggest that the formation and transfer of 27OHC-esters are
more sensitive to reduced activities of LCAT and CETP, respectively, than the formation and transfer of
cholesterylesters. 27OHC plasma levels were also decreased in apoA-I-, ABCA1- or LCAT-knockout mice
but increased in SR-BI-knockout mice. Transplantation of ABCA1- and/or ABCG1-deﬁcient bone mar-
row into LDL receptor deﬁcient mice decreased plasma levels of 27OHC. In conclusion, mutations or
absence of HDL genes lead to distinct alterations in the quantity, esteriﬁcation or lipoprotein distribution
of 27OHC. These ﬁndings argue against the earlier suggestion that 27OHC-metabolism in plasma occurs
independently of HDL.
. Introduction
27-Hydoxycholesterol (27OHC) is a metabolite of choles-
erol formed by the mitochondrial cytochrome P450 sterol
7-hydroxylase (CYP27), an enzyme particularly expressed in the
ascular endothelium, macrophages and the liver [1,2]. Intro-
uction of a hydroxyl group allows the otherwise hydrophobic
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cholesterol molecule to pass amphiphilic membranes more easily
[2,3]. Becauseof thesephysicochemical properties, 27OHChasbeen
postulated to be secreted from cells independently of transporters
and extracellular lipoprotein acceptors and thereby to facilitate an
alternative route for apolipoprotein (apo) A-I/high density lipopro-
teins (HDL)-mediated transportof cholesterol frommacrophages to
the liver [2]. In the liver, 27OHC is an important intermediary prod-
uct of the so-called alternative bile acid synthesis pathway which
contributes ∼10% to de novo bile acid biosynthesis [2]. In addition,
Open access under the Elsevier OA license.27OHC is an important ligand of at least two types of nuclear hor-
mone receptors. It activates liver-X-receptors (LXR) alpha and beta
which regulate the transcription of several genes involved in lipid
and lipoproteinmetabolism [4,5].Most recently 27OHCwas identi-
ﬁed as the ﬁrst endogenous selective estrogen receptor modulator
scleros
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SERM). Both in vitro and in vivo 27OHC was found to modulate
he transcriptional activity of estrogen receptors tissue-speciﬁcally
ither as an agonist or antagonist [6].
27OHC is the most abundant oxysterol in the circulation [4],
hile plasma levels of 27OHC have been found to correlate with
he cholesterol content in atherosclerotic lesions and the severity
f coronary artery disease [7]. Patients with genetic CYP27 deﬁ-
iency suffer from cerebrotendinous xanthomatosis and develop
remature atherosclerosis despite having normal levels of plasma
holesterol [2]. Taken together, 27OHC has been proposed to be an
nti-atherogenic molecule [2,8].
Since the classical reverse cholesterol transport is mediated
y HDL, and because HDLs are important carriers of 27OHC
n plasma [9], we investigated whether monogenic disorders of
DL metabolism affect plasma and lipoprotein concentrations of
7OHC. We used an LC–MS method which allows to quantify
7OHC in small plasma volumes (15–50L) [10]. Speciﬁcally, we
nalysed plasmas of patients with functionally relevant mutations
r mice with knock-outs of the following genes: apoA-I which is
he main protein component of HDL; ATP-binding cassette trans-
orters A1 (ABCA1) and G1 (ABCG1) which mediate cholesterol
nd phospholipid efﬂux from cells to apoA-I and HDL, respectively;
ecithin:cholesterol acyl transferase (LCAT)which esteriﬁes choles-
erol and thereby converts discoidal HDL precursors into mature
pherical HDL particles; cholesterylester transfer protein (CETP,
ot expressed in mice) which exchanges cholesterylester of HDL
gainst triglycerides of apoB-containing lipoproteins; scavenger
eceptor type B I (SR-BI)whichmediates selective uptake of choles-
erol esters in the liver and steroidogenic organs; andhepatic lipase
HL, only studied in humans) which hydrolyses triglyceride and
hospholipids in HDL [11]. Through this analysis, we identiﬁed
ariations in HDL concentrations as well as the activities of ABCA1,
BCG1, LCAT and CETP as factors regulating 27OHC metabolism in
lasma.
. Methods
.1. Patient plasmas
Forty-one Dutch patients with functionally relevant mutations
n the genes encoding for either LCAT, ABCA1, APOA1, SR-BI, CETP
r HL as well as 41 unaffected family members were investigated.
ost of the families and the underlying defects were described
reviously [12–16]. In addition, 4 Danish patients with mutations
n APOA-I or CETP as well as 5 age- and sex-matched controls
ere included. The Medical Ethics Committee of the Academic
edical Center (AMC) in Amsterdam, The Netherlands, as well as
he Danish Ethics Committee for Copenhagen and Frederiksberg,
enmark, approved all genetic and phenotypic studies described
nd all participants signed an informed consent to join the study.
he characteristics of the study participants are shown in Table 1.
asting blood sampleswere collected after at least a 10-h fast in the
orning and EDTA-plasmawas prepared through centrifugation of
he blood at 3000 rpm for 10min at 25 ◦C by the study nurses of the
MC, Amsterdam, The Netherlands, and of the Department of Clin-
cal Biochemistry, Rigshospitalet, Copenhagen, Denmark. Aliquots
ere immediately frozen at −80 ◦C until later use.
.2. Mouse plasmasAll animal procedures were approved by the Bioethical com-
ittee of the Biomedical Research Institute of the Academy of
thens and Leiden University. All animal experimentations were
n agreement with the ethical recommendation of the European
ommunities Council Directive (86/609/EEC).is 214 (2011) 448–455 449
Knock-out as well as C57B/6 control mice were purchased
from Jackson Laboratory (Bar Harbor, ME, USA) and maintained
on standard chow diets containing 5% fat (Harlan Teklad, Madi-
son, WI, USA). Mice were fasted for 6h before the collection
of blood samples. Samples from mutants and wild-type control
mice were collected in EDTA-containing eppendorf tubes, kept
in room temperature for 20min and centrifuged to collect the
plasma. All samples were stored in −80 ◦C and transported in dry
ice.
Bone marrow transplantation was conducted by Division of
Biopharmaceutics, Leiden/Amsterdam Center for Drug Research,
LeidenUniversity, The Netherlands [17]. Bone marrow transplant
mice aswell as their controlswere fedwithWesterndiet containing
0.25% cholesterol.
2.3. Quantiﬁcation of 27OHC
The concentrations of 27OHC in total and apoB-depleted plasma
were analysed using a dopant assisted-atmospheric pressure pho-
toionization (DA-APPI) liquid chromatography–mass spectrometry
(LC–MS) method as described previously [10]. For the quantiﬁca-
tion of unesteriﬁed 27OHC, the hydrolysis step was omitted and
the sample volume was increased to 100L due to the very low
endogenous level of free 27OHC (only ∼10–20% of total 27OHC)
[9].
For the determination of 27OHC in HDL, apoB-containing
lipoproteins were removed from 100L human EDTA plasma by
precipitation with dextran-sulfate-Mg2+ [18]. 27OHC concentra-
tions assayed in apoB-depleted plasma were multiplied by 1.1 to
correct for the dilution and to obtain the concentration of 27OHC
in HDL. The difference between the concentrations of total 27OHC
and HDL-27OHC was described as nonHDL-27OHC concentration.
We have shown previously that this method recovers about 95%
of 27OHC in the apoB-depleted fraction, as compared to density-
gradient ultracentrifugation, and that nearly 90% of plasma 27OHC
is contained in the lipoprotein fractions [9].
2.4. Quantiﬁcation of other lipids, apolipoproteins, LCAT and CETP
Total plasma cholesterol, triglycerides, HDL-cholesterol, and
LDL-cholesterol, apoB, apoA-I, and apoA-II levels were measured
withcommercial kits (Wako,Neuss,GermanyandRandox,Crumlin,
UK) on a Cobas Mira autoanalyzer. Due to the limited sensitiv-
ity of the enzymatic homogenous assay, concentrations of HDL
cholesterol as well as thereof derived measures (nonHDL choles-
terol and the ratios of 27OHC/cholesterol in HDL and nonHDL) are
not reported for patients with virtually complete HDL deﬁciency,
namely the homozygotes and compound heterozygotes for muta-
tions in ABCA1 or LCAT.
The unesteriﬁed cholesterol concentrations in the super-
natant after precipitation of apoB-containing lipoproteins
with polyethylenglycol were assayed using a procedure that
has been developed in house. Brieﬂy, a mixture of reagent
(200L) containing 7.3mg/mL homovanilic acid, 0.1M 3-
[N-Morpholine]propanesulfonic acid, 1.25mM taurocholate,
1.35U/mL cholesterol oxidase and 10U/mL peroxidase was added
to 30L sample and assayed using the FLUOstar Galaxy ﬂuorom-
eter (BMG Labtech, Offenburg, Germany). The assay was based on
the reaction of cholesterol with oxygen to give hydrogen peroxide,
which subsequently reacted with homovanilic acid to give a
ﬂuorescence emission at 450nm wavelength. Cholesterylester
concentrations were calculated as the differences of total and
unesteriﬁed cholesterol concentrations.
LCAT activity and cholesterol esteriﬁcation rates were deter-
mined using proteoliposomes containing radioactive cholesterol
as the exogenous substrate assay and after equilibration of plasma
450 R. Karuna et al. / Atherosclerosis 214 (2011) 448–455
Table 1
Characteristics of the mutation carriers and their unaffected family members.
Mutated gene Number of
defective alleles
Mutationa Age (year) Cholesterol
(mM)
HDL-
cholesterol
(mM)
NonHDL-
cholesterol
(mM)
Triglyceride
(mM)
Number of
smokers
Dutch
APOA1 0 27 ± 14 4.59 ± 0.68 1.16±0.06 3.43±0.63 1.09 ± 0.29 0
1 p.L202P (c.605T>C) 26 ± 17 3.61 ± 0.31 0.51±0.35 3.10±0.06 1.09 ± 0.51 0
ABCA1 0 44 ± 20 4.39 ± 0.89 1.47±0.39 2.92±0.62 0.95 ± 0.22 1
1 p.L1056P (c.3167T>C)
or p.C1477R
(c.4429T>C)
57 ± 11 4.47 ± 1.08 0.94±0.17 3.53±0.96 1.01 ± 0.05 0
2 p.L1056P (c.3167T>C,
homozygote) or
p.Q1038X
(c.3112C>T) +p.N1800H
(c.5398A>C) or
p.C1477R
(c.4429T>C) + IVS25+1G>C
53 ± 10 2.89 ± 2.39 NDb NDb 2.29 ± 1.80 0
LCAT 0 49 ± 9 4.96 ± 0.86 1.33±0.38 3.62±0.97 1.29 ± 0.66 0
1 p.T147I (c.440C>T),
p.R322C (c.964C>T),
p.N155D (c.463A>G),
p.P34Q (c.101C>A),
p.Y107X (c.321C>A),
p.I202T (c.605T>C) or
p.V333M (c.997G>A)
43 ± 13 4.27 ± 1.21 0.81±0.28 3.45±1.08 1.30 ± 0.55 1
2 p.T147I
(c.440C>T) +V333M
69 ± 4 3.26 ± 0.19 NDb NDb 2.11 ± 0.49 0
SR-BI 0 54 ± 19 4.77 ± 0.89 1.17±0.33 3.60±0.79 1.21 ± 0.64 0
1 p.P297S (c.889C>T) 45 ± 22 4.46 ± 1.21 1.73±0.56 2.73±0.81 0.97 ± 0.28 1
CETP 0 36 ± 16 4.14 ± 0.51 1.30±0.21 2.85±0.48 0.87 ± 0.40 1
1 IVS7+1 (G>T) 39 ± 18 4.20 ± 0.51 1.56±0.29 2.64±0.77 0.76 ± 0.32 1
HL (LIPC) 0 45 ± 19 5.23 ± 0.99 1.61±0.54 3.62±0.90 1.45 ± 1.05 3
1 p.S289F (c.866C>T) 45 ± 15 4.92 ± 1.21 2.00±0.68 2.92±0.86 1.14 ± 0.43 1
Danish
Controls 0 50 ± 9 5.84 ± 1.24 1.54±0.24 4.30±1.23 1.34 ± 0.62 1
APOA1 1 p.L168R (c.503T>G) 63 ± 4 4.70 ± 0.28 0.85±0.07 3.85±0.35 1.27 ± 0.70 0
CETP 1 p.S349Y (c.1046C>A) 59 ± 4 6.85 ± 2.05 3.05±1.77 3.80±0.28 0.86 ± 0.23 1
V
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a Amino acid changes are localized on the basis of the entirely translated protein
orrect apoA-I by −24 amino acids, ABCA1 by −60 amino acids, LCAT by −24 amino
b Not determined (ND).
ith 3H-cholesterol as the endogenous substrate, respectively [19].
ETP concentration was measured as described [20].
.5. Statistical analysis
Statistical analyses were performed using Microsoft Excel
Microsoft, Redmont, WA, USA) and SPSS 17.0 (SPSS, Chicago, IL,
SA). Normal distribution was tested using Kolmogorov–Smirnov
est. Since thedatadistributionwasnormal, unpaired student t-test
as used to test for statistical signiﬁcances of differences between
groups (assuming equal variance). Signiﬁcance of a correlation
as tested from the Pearson’s correlation coefﬁcient (r).
. Results
.1. Effects of gender, age and statin treatment on 27OHC levels
n humans
Because of a strong effect of gender on plasma 27OHC levels
9], we stratiﬁed our data by sex. Because 27OHC concentrations
n plasma are only mildly affected by age [9], we did not further
djust the data for age. About 35% of all probands were treated
ith statins. However, when comparing family controls with and
ithout statin treatment, this did not appear to affect plasma- and
DL-27OHC concentrations: 0.47±0.07M vs. 0.50±0.15M,
nd 0.20±0.05M vs. 0.23±0.15M, respectively. Also other
ommon medications including oral contraceptives, beta block-is including the signal peptides. To deﬁne the position within the mature protein,
, SR-BI by 0 amino acids, CETP by −17 amino acids, HL by −22 amino acids.
ers, calcium channel blockers, angiotensin converting enzyme
inhibitors as well diuretics were not associated with statistically
signiﬁcant differences of 27OHC concentrations in plasma, HDL or
nonHDL, and we therefore did not stratify the data for statin or any
other drug treatment.
3.2. Effects of human inborn errors of HDL metabolism on 27OHC
levels
In Table 2, we compared the concentrations of 27OHC in total
plasma, HDL and nonHDL. As shown previously [9], we identiﬁed
highly signiﬁcant and similar positive correlations between 27OHC
and cholesterol levels in total plasma, HDL and nonHDL fractions
(see Fig. 1). The r-square values obtained by univariate regression
analysis of data indicate that variations in total cholesterol, HDL
cholesterol and nonHDL cholesterol explain 35–40% of the variance
in plasma concentrations of total 27OHC,HDL-27OHCandnonHDL-
27OHC, respectively. The correlation plots as well as the ratios
of 27OHC to cholesterol (Fig. 1 and Table 2) allowed us to iden-
tify those conditions in which 27OHC levels were altered beyond
cholesterol levels.
Homozygous defects in LCAT and ABCA1 were associated
with signiﬁcantly increased 27OHC/cholesterol ratios in plasma
(Table 2). All other differences in plasma concentration of 27OHC
between carriers of other gene defects and family controls were
either not statistically signiﬁcant or not consistent: Male but not
female SR-BImutation carriers showed lower 27OHC plasma levels
as compared to allmale controls, but not as compared to unaffected
R. Karuna et al. / Atherosclerosis 214 (2011) 448–455 451
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Fig. 1. Plots of 27OHC vs. cholesterol concentrations in plasma (A), HDL (B) and nonHDL (C) of individuals with mutations in HDL genes and their unaffected relatives. The
c ed fam
2 ll as th
t
m
l
a
t
dorrelations and regression equations have been calculated on data from all unaffect
7OHC concentrations in plasma, HDL and nonHDL of LCAT mutation carriers as we
he carriers of HL mutations.
ale relatives from the same family. The signiﬁcantly decreased
evels of 27OHC plasma levels in male and female carriers of the
poA-I(p.L202P) mutant were not retrieved in individuals carrying
he apoA-I(p.L168R) mutation (Table 2).
Defects in LCAT and ABCA1 were associated with gene-dosage-
ependent decreases of HDL-27OHC levels. Heterozygous carriersilymembers (“Controls” of Tables 1 and 2). Please note the biases towards elevated
e biases towards higher HDL-27OHC and lower nonHDL-27OHC concentrations in
of apoA-I mutations also showed signiﬁcantly decreased 27OHC
levels in HDL. Conversely, defects that increase HDL-cholesterol
levels also tended to be associated with an increase of HDL-27OHC
levels (Table 2 and Fig. 1B). However, this effect was statistically
signiﬁcant only for male CETP and HL mutation carriers. After
normalisation for HDL-cholesterol levels, defects in LCAT showed
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consistent and statistically signiﬁcant associations with increased
HDL-27OHC/HDL-cholesterol ratios (Table 2).
Finally, 27OHC levels and the ratio of 27OHC/cholesterol were
increased in the nonHDL fractions of ABCA1 mutation carriers and
female LCAT mutation carriers (Table 2 and Fig. 1C). By contrast,
male heterozygotes for defects in apoA-I, SR-BI, CETP or HL had
lower nonHDL-27OHC levels as compared to the unaffected male
controls (Table 2). In HL mutation carriers, nonHDL-27OHC lev-
els and nonHDL-27OHC/nonHDL-cholesterol ratiowere lower than
in unaffected controls from either the same families or the entire
population (Table 2 and Fig. 1C).
3.3. Effects of LCAT and CETP mutations on esteriﬁed 27OHC in
humans
LCAT activity was decreased to about 75% of normal in female
and male heterozygotes for LCAT defects (Table 3). This 25%
decrease in LCAT activity affected neither the esteriﬁcation nor
the cholesterylester/total cholesterol ratios in total plasma and
HDL. By contrast, the percentage of 27OHC-ester was signiﬁcantly
decreased while the ratio of free-27OHC/free-cholesterol was sig-
niﬁcantly increased in both plasma and HDL of heterozygous LCAT
mutation carriers as compared to unaffected family members.
Regression analysis revealed a stronger correlation of LCAT activ-
ity with 27OHC-ester concentration than with cholesterylester
concentration in HDL (r=0.6528, p≤0.001 vs. r=0.0538, p≤0.01,
respectively; seeSupplemental Fig. 1). Interestingly, thepercentage
of esteriﬁed 27OHC was also signiﬁcantly decreased in plasma and
HDL of heterozygous apoA-I(p.L202P) carriers, but not of heterozy-
gotes for the apoA-I(p.L168R) mutation. This ﬁnding is surprising
because both in vitro and in vivo the p.L168R substitution rather
than the p.L202P substitution was found to reduce the LCAT cofac-
tor activity of apoA-I (V.I. Zannis, A. Tybjaerg Hansen, J. Albert
Kuivenhoven; personal communication).No signiﬁcant changeswere
observed in the degree of 27OHC-esteriﬁcation in carriers of ABCA1
defects.
Heterozygosity for the Dutch CETP mutations was associated
with decreased absolute and relative concentrations of 27OHC-
esters in the nonHDL fraction but no differences in the HDL fraction
(Table 3). Despite half normal CETP concentration and CETP activity
[16] the concentrations andpercentages of cholesterylesters inHDL
or nonHDLwere not affected. Regression analysis revealed a signif-
icant correlation of CETP mass concentration with both absolute
and relative 27OHC-ester concentrations in nonHDL (r2 =0.337,
p=0.0092 and r2 =0.276, p=0.029, respectively), but insigniﬁcant
correlations with absolute and relative cholesterylester concen-
trations in nonHDL (r2 =0.077 and r2 =0.029, respectively) (see
Supplemental Fig. 2).
3.4. 27OHC in mice with various knock-outs of HDL genes
In normal murine plasma both cholesterol and 27OHC are
almost exclusively carried byHDL (Supplemental Table).We there-
fore analysed the different genetic mouse strains for total 27OHC
plasma levels only. Compared to wild-type mice, apoA-I- or LCAT-
knockout mice were characterized by more than 50% lowered
plasma 27OHC concentrations, whereas SR-BI knockout mice had
about 5-fold higher 27OHC levels. After normalization for total
cholesterol, the differences remained statistically signiﬁcant for
LCAT and SR-BI knock-out mice only. In addition and compared
to wild type mice, ABCA1 deﬁcient mice showed a 140% increased
27OHC/cholesterol ratio (p<0.001) in the presence of 25% lower
27OHC levels (p<0.05, Table 4). Interestingly, heterozygous ABCA1
knock-out mice showed a similar decrease in 27OHC plasma levels
which did not result in a signiﬁcantly altered 27OHC/cholesterol
ratio (Table 4) due to the equal decrease in cholesterol levels.
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Table 3
Esteriﬁcation of 27OHC and cholesterol in plasma and lipoproteins of LCAT and CETP mutation carriers and their unaffected family controls.
LCAT mutation carriers CETP mutation carriers
Unaffected family
members (“0”)
Heterozygous
mutants (“1”)
Unaffected family
members (“0”)
Heterozygous
mutants (“1”)
Number (male/female) 5/3 8/4 2/1 2/1
LCAT activity (nmol cholesteryl ester/h×mL) 8.37±1.21 6.58±1.01*** N.D. N.D.
CETP mass (g/mL) 2.12±0.40 1.73±0.32* 1.93±0.33 0.90±0.21**
% 27OHC-ester in plasma 92.3±6.7 89.8±4.3 83.8±4.3 75.4±4.0
% cholesteryl ester in plasma 87.7±2.4 88.4±1.4 67.6±0.6 66.7±1.1
Ratio 27OHC-ester (M)/cholesteryl ester (mM) in plasma 0.16±0.04 0.16±0.03 0.18±0.08 0.14±0.01
Ratio unesteriﬁed 27OHC (M)/unesteriﬁed cholesterol (mM) in plasma 0.09±0.06 0.15±0.08 0.07±0.01 0.09±0.02
% 27OHC-ester in HDL 88.4±4.4 79.8±10.6* 78.5±13.5 81.9±2.6
% cholesterol esters in HDL 80.9±3.0 82.5±3.6 77.9±2.3 75.7±2.4
Ratio 27OHC-ester (M)/cholesteryl ester (mM) in HDL 0.22±0.06 0.21±0.07 0.27±0.10 0.28±0.11
Ratio unesteriﬁed 27OHC (M)/unesteriﬁed cholesterol (mM) in HDL 0.12±0.04 0.28±0.20* 0.23±0.07 0.21±0.11
% 27OHC-ester in nonHDL 93.3±23.9 95.8±9.6 88.9±5.7 67.0±9.6*
% cholesterol esters in nonHDL 92.5±1.4 91.4±2.0 64.5±1.0 63.4±1.1
.13±0
.14±0
* 01, res
t
r
w
(
m
2
A
2
d
A
A
h
7
r
4
a
e
e
f
c
T
2
w
o
*
tRatio 27OHC-ester (M)/cholesteryl ester (mM) in nonHDL 0
Ratio unesteriﬁed 27OHC (M)/unesteriﬁed cholesterol (mM) in nonHDL 0
, ** and *** indicate statistically signiﬁcant differences (p<0.05, p<0.01 and p<0.0
To investigate the contribution of macrophage-derived 27OHC
o plasma 27OHC levels, we also analysed the plasmas of LDL
eceptor-deﬁcient mice who received bone marrow from mice
ith knockouts of either ABCA1, ABCG, or both ABCA1 and ABCG1
Table 4). Notably in parallel with hypercholesterolemia, LDLR−/−
ice had 20-fold higher 27OHC concentrations and 2-fold higher
7OHC/cholesterol ratios than wild-type mice. Transplantation of
BCA1- or ABCG1-deﬁcient bone marrow resulted in 45% and
3% decreases of 27OHC plasma levels as well as in signiﬁcantly
ecreased 27OHC/cholesterol ratios (p<0.05 for ABCA1; p<0.01 for
BCG1).Micewithbonemarrowfrommicewithknock-outsofboth
BCA1 and ABCG1 had even 66% lower mean 27OHC plasma levels,
owever, thiswas seen in the context of a slightlymorepronounced
0% decrease in cholesterol levels so that the 27OHC/cholesterol
atio was rather increased.
. Discussion
27OHC plays an important physiological role as an intermedi-
ry product of cholesterol removal from speciﬁc tissues and the
ntire organism aswell as an agonist andmodulator of liver-X- and
strogen receptors, respectively [9,21]. We have previously shown
or normolipidemic individuals that about 50%, 30% and 5% of cir-
ulating 27OHC in healthy individuals are recovered in HDL, LDL
able 4
7OHCplasma levels inmicewithknock-outs of LCAT (LCAT−/−), APOA-I (APOA1−/−), ABC
hich received bone-marrow fromeitherwild typemice (LDLR−/−:BMTwt) ormicewith k
r both ABCA1 and ABCG1 (LDLR−/−:BMTABCA1−/−×ABCG1−/−).
Mouse strains Number of mice (n) 27OHC
Wild type 28 0.15 ±
APOA-I−/− 5 0.06 ±
ABCA1−/− 6 0.11 ±
ABCA1+/− 3 0.08 ±
LCAT−/− 8 0.06 ±
SR-BI−/− 10 0.96 ±
LDLR−/−:BMT wt 6 3.33 ±
LDLR−/−:BMTABCA1−/− 6 1.88 ±
LDLR−/−:BMTABCG1−/− 6 2.57 ±
LDLR−/−:BMTABCA1−/−×ABCG1−/− 9 1.11 ±
, **, and *** indicate statistically signiﬁcant differences (p<0.05, p<0.01, and p<0.001, re
ype bone marrow..06 0.14±0.05 0.14±0.04 0.07±0.01
.19 0.10±0.10 0.03±0.02 0.07±0.04
pectively) between “1” and “0”.
and VLDL, respectively [9]. However, the plasma concentration of
27OHC is 10,000-fold lower than that of cholesterol (0.5mol/L
vs. 5mmol/L on average). It is even considerably lower than the
particle concentration of HDL (on average 20mol/L) and LDL (on
average 2mol/L) so that only a minority of lipoprotein parti-
cles carries 1 or more molecules of 27OHC. The very low plasma
and lipoprotein concentrations of 27OHC, the signiﬁcant correla-
tionsbetween27OHCandcholesterol concentrations inplasmaand
lipoproteins [9] as well as the higher water-solubility of 27OHC
compared to cholesterol [3] raised the question whether 27OHC
is passively equilibrated among the various lipoprotein classes or
speciﬁcally metabolized in plasma similar to cholesterol, that is
by established transporters, enzymes, lipid transfer proteins and
receptors. Some general support for the latter assumption could
already be derived from the enrichment of 27OHC relative to
cholesterol in HDL (on average 47±7% of plasma 27OHC instead of
33±6% plasma cholesterol) [9] and from the 10% higher percent-
ages of 27OHC-esters relative to cholesterylesters in plasma, HDL
and LDL [9]. We here further explored this question by analysing
27OHC concentrations in plasma as well as HDL- and nonHDL-
fractions of patients and mice with distinct monogenic disorders
of HDL metabolism.
In the present study correlations between 27OHC and choles-
terol concentrations in plasma and HDL were similar or even
A1 (ABCA1−/−) or SR-BI (SRBI−/−) aswell as LDL receptordeﬁcientmice (LDLR−/−)
nock-outs of either ABCA1 (LDLR−/−:BMTABCA1−/−), ABCG1 (LDLR−/−:BMTABCG1−/−)
(mol/L) Cholesterol (mmol/L) Ratio
total-27OHC/total-
cholesterol
(mol/mmol)
0.08 1.81 ± 0.55 0.08 ± 0.04
0.04* 1.24 ± 0.43*** 0.05 ± 0.05
0.06 0.68 ± 0.50*** 0.19 ± 0.08***
0.01 1.43 ± 0.21 0.06 ± 0.01
0.02** 2.28 ± 1.08 0.03 ± 0.01***
0.32*** 3.27 ± 0.73*** 0.29 ± 0.10***
1.32 20.44 ± 7.83 0.16 ± 0.03
0.26* 15.56 ± 2.89 0.13 ± 0.03*
0.52 23.86 ± 3.02 0.11 ± 0.03**
0.25*** 6.09 ± 1.55*** 0.19 ± 0.07
spectively) as compared to wild type mice or LDLR−/− mice transplanted with wild
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tronger than those reported by us previously, namely 0.59 instead
f 0.54 in total plasma, and 0.64 instead of 0.34 in HDL (Fig. 1 and
9]). Independently of themetabolic or genetic origin, differences in
DL cholesterol appear to explain up to 40%of the variation inHDL-
7OHC levels. As a consequence, functionally relevantmutations in
poA-I, ABCA1 and LCAT that decrease HDL-cholesterol were asso-
iated with reduced concentrations of 27OHC in HDL. Monoallelic
nd biallelic mutations, which could only investigated for ABCA1
nd LCAT, led to gene-dose-dependent decreases of HDL-27OHC
evels. Likewise, HDL deﬁcient mice with knock-outs of apoA-I or
CAT presented with decreased 27OHC plasma levels. Conversely,
7OHC or HDL-27OHC plasma levels were strongly elevated in
R-BI knock-out mice as well as in male carriers of mutations in
he genes of CETP, SR-BI and HL. The reason for the absent effect
f the HDL-cholesterol increasing mutations on 27OHC levels in
omen might be related to the strong regulation of HL and SR-BI
y estrogens [22,23], since 27OHC is amodulator of estrogen recep-
or activity [9,21]. Onemay speculate that this interaction of 27OHC
nd estrogens in the regulation of SR-BI and HL leads to differences
n the metabolism of cholesterol and 27OHC between males and
emales.
At ﬁrst sight, in both humans and mice with inborn errors of
DL metabolism, HDL-27OHC levels appeared simply to change
assively in parallel with HDL-cholesterol levels. However, in
he light of the previously suggested concept that 27OHC may
epresent an HDL-independent pathway of reverse cholesterol
ransport [2] our ﬁndings in patients with defects in ABCA1, LCAT
r CETP as well as mice with either systemic or macrophage
peciﬁc knockouts of ABCA1 and ABCG1 deserve special
ttention.
.1. ABCA1 and ABCG1
27OHC secretion has been suggested to represent an alterna-
ive pathway to HDL- and apoA-I-mediated cholesterol efﬂux by
hich macrophages protect themselves from cholesterol overload
2]. However, this hypothesis was generated based on experi-
ents that had been performed before the discovery of ABCA1 and
BCG1 as important cholesterol efﬂux pumps and their involve-
ent in 27OHC efﬂux has not yet been tested directly. ABCA1 and
BCG1 were however shown to mediate the efﬂux of two other
xysterols, namely 25-hydroxycholesterol and 7-ketocholesterol,
espectively [24,25]. The current data show normal 27OHC plasma
evels in the presence of decreased cholesterol levels and hence
ncreased 27OHC/cholesterol ratios in both ABCA1 deﬁcient Tang-
er patients and ABCA1 knock-out mice suggesting that 27OHC
s secreted independently from ABCA1. However, transplantation
f bone marrow from ABCA1- or ABCG1-knock out mice sig-
iﬁcantly decreased 27OHC/cholesterol ratios. The mice which
eceived bone marrow of mice with a combined knock-out of
BCA1 and ABCG1 showed the most prominent decrease of both
7OHC and cholesterol levels so that the 27OHC/cholesterol ratio
as not decreased. Nevertheless, we interpreted the data as an
ndication that both ABCA1 and ABCG1 contribute to 27OHC-efﬂux
rom macrophages. Our contradiction to the concept of an HDL-
ndependent reverse cholesterol transport pathway mediated by
7OHC in humans is also supported by the enrichment of 27OHC
elative to cholesterol in HDL, the strong correlation between
DL-cholesterol and HDL-27OHC in the normolipidemic human
opulation as well as the parallel changes of HDL-cholesterol
nd HDL-27OHC observed in almost all human heterozygotes for
DL-related gene defects. Although not proven by us directly,
ur ﬁndings rather suggest that 27OHC secretion involves HDL-
ediated efﬂux pathways that are supported by ABCA1 or ABCG1
26].is 214 (2011) 448–455
4.2. LCAT
In both genders of humans, mutations in LCAT caused relatively
less pronounced decreases in HDL-27OHC than HDL-cholesterol
levels in comparison with unaffected family members, the entire
control population aswell as other genetic lowHDLconditions. This
ﬁnding is surprising because about 90% of 27OHC in normal HDL
but only about 80% of 27OHC in HDL of heterozygous LCAT muta-
tion carriers is esteriﬁed. The elevated 27OHC/cholesterol ratio in
LCAT mutation carriers is hence the result of a relatively high con-
centration of unesteriﬁed 27OHC, rather than of esteriﬁed 27OHC.
It thus appears that reduced LCAT activity increases the capacity of
HDL particles to accommodate unesteriﬁed 27OHC, for example as
the consequence of a higher content in phosphatidylcholine or an
increased number of small HDL particles.
In both plasma and HDL, the proportions of 27OHC-esters
in total 27OHC are about 10% higher than the proportions of
cholesterylesters in total cholesterol (Table 3 and [9]). More-
over, heterozygous LCAT mutation carriers showed reduced
27OHC-ester/total-27OHC ratios, but normal cholesterylester/total
cholesterol ratios, in HDL. Finally, LCAT activity showed a
stronger correlation with 27OHC-ester concentrations than with
cholesterylester concentrations in HDL (r2 =0.426, p≤0.001 vs.
r2 =0.290, p≤0.01, respectively; see Supplemental Fig. 1). Together
the data thus suggest that 27OHC ismore readily esteriﬁed by LCAT
and more sensitive to impairments of LCAT activity than choles-
terol. Our observational data do not allow any conclusion on the
biochemical basis for thehigher sensitivity of 27OHC towards LCAT.
One reason could be differences in the reaction kinetics (afﬁnity
and/or maximal reaction velocity) of LCAT towards 27OHC and
cholesterol, so that reduced LCAT activity in mutation carriers
affects 27OHC-esteriﬁcation more strongly than cholesterol ester-
iﬁcation. Importantly, 27OHC has a second free hydroxyl-group in
the side chain in addition to the 3-hydroxyl-group of the sterol
which, by contrast to free hydroxyl-groups of other oxysterols, can
also be esteriﬁed by LCAT [27]. Therefore, in theory, the stronger
impact of LCAT activity on 27OHC-esteriﬁcation may reﬂect the
abundance of different 27OHC-ester species. Unfortunately our
method did not allow for a direct and differentiated quantiﬁca-
tion of 27OHC-esters. We rather estimated the concentrations of
all 27OHC-esters from the differences between total and unesteri-
ﬁed 27OHC which were measured after and before saponiﬁcation,
respectively. We therefore cannot rule out that the higher con-
centration of 27OHC-esters relative to cholesterol esters in normal
controls reﬂects the abundance of additional 27OHC-ester species
and that the decreased 27OHC-ester formation in LCAT muta-
tion carriers results from a speciﬁc loss of function towards the
27-hydroxyl-group. However, LCAT was reported to esterify the
27-hydroxyl-group only after esteriﬁcation of the 3-hydroxyl-
group, so that 27OHC-esters were postulated to occur as either
3-hydroxyl-monoesters or 3/27-dihydroxyl esters only [27]. If
so, our ﬁnding of decreased 27OHC-esters in heterozygous LCAT
mutation carriers cannot be explained by a selectively reduced
activity to esterify the 27-hydroxyl-group.
4.3. CETP
Both in the nonHDL fraction (this study) and LDL [9], more
than 90% of 27OHC is esteriﬁed. To our knowledge the origin
of these esters has not yet been explored directly. In analogy to
cholesterylesters, 27OHC-esters of apoB containing lipoproteins
may originate either from intrahepatic production by acyl-
CoA:cholesterol acyltransferase (ACAT) and subsequent secretion
together with VLDL [28,29] or from LCAT-mediated production
eitherdirectlyonapoB-containing lipoproteinsor indirectlyonHDL
and subsequent CETP mediated transfer. ACAT has been shown
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o esterify most oxysterols with much less efﬁcacy than choles-
erol [28] but its contribution to 27OHC-esteriﬁcation has not been
xplored. Unlike in HDL, the percentage of 27OHC-esters in non-
DL was not altered by heterozygous defects in LCAT suggesting
hat LCAT does not play a rate limiting role for 27OHC-ester for-
ation in LDL. Alternatively, since many of the LCAT mutants
nalysed by us were found in patients with ﬁsh-eye disease
14,15,19], these mutants may have retained beta-LCAT activ-
ty, that is the ability to esterify cholesterol in apoB-containing
ipoproteins [14,15,19]. Most interestingly and informative, how-
ver, heterozygosity for CETP defects was associated with reduced
bsolute and relative concentrations of 27OHC-esters in the non-
DL fraction but normal concentrations in HDL. This suggests
hat CETP mediates the transfer of 27OHC-esters between HDL
nd apoB-containing lipoproteins. This binding and transport
apacity of CETP has not yet been proven directly for 27OHC-
sters but for 25-hydroxycholesterol esters [30]. Compared to
holesterylester transfer, the efﬁcacy of 27OHC-ester transfer
ppears to be even more sensitive to changes in CETP activ-
ty because apoB-containing lipoproteins of heterozygous CETP
utation carriers contained normal concentrations and percent-
ges of cholesterylesters. Furthermore, CETP mass concentrations
howed statistically signiﬁcant correlations with absolute and rel-
tive concentrations of 27OHC-esters in nonHDL but no signiﬁcant
orrelations with either absolute or relative cholesterylester con-
entrations in nonHDL (see Supplemental Fig. 2).
In conclusion, mutations in several HDL genes lead to general
lterations in the quantity of 27OHC in HDL and plasma as well as
peciﬁc changes in the esteriﬁcation and lipoprotein distribution
f 27OHC. In general, changes in the concentration of HDL choles-
erol areparalleledbyequidirectional changesofHDL-27OHC levels
ndicating that HDL acts as a passive acceptor and transporter of
7OHC and to explain up to 40% of the variation in HDL-27OHC
evels. More speciﬁcally our data from mice with macrophage spe-
iﬁc knock out of ABCA1 and ABCG1 refutes the notion that 27OHC
s efﬂuxed from macrophages by HDL-independent pathways. In
ddition esteriﬁcation and transfer of 27OHC (esters) appear to
e more sensitive towards changes in the activities of LCAT and
ETP than cholesterol. It hence appears that reverse transport of
7OHC is even more strongly inﬂuenced by HDL metabolism than
holesterol. In view of the role of 27OHC as a tissue speciﬁc mod-
lator of transcription factors, future studies will have to show
hether these speciﬁc aspects in theplasmametabolismand trans-
ort of 27-hydroxycholesterol have implications for health and
isease.
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